Larvol Delta - Brenig-Therapeutics-Announces-Oral-Presentation-of-Phase-1-Data-for-BT267-at-ADPD-2026-and-Provides-Updates-on-BT409-its-NLRP3-Inhibitor-Program

BT-267 - Brenig Therap

BT-409 - Brenig Therap

https://www.prnewswire.com/news-releases/brenig-therapeutics-announces-oral-presentation-of-phase-1-data-for-bt-267-at-adpd-2026-and-provides-updates-on-bt-409-its-nlrp3-inhibitor-program-302716533.html

Mar 17, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next